Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Biocad
ClinicalTrials.gov Identifier:
NCT01766024
First received: January 10, 2013
Last updated: January 10, 2014
Last verified: December 2013
  Purpose

This is a randomized double-blind crossover study of pharmacokinetics, pharmacodynamics and tolerability of BCD-033 (interferon beta-1a manufactured by CJSC BIOCAD, Russia) and Rebif® (Merck Serono S.p.A.., Italy) in healthy volunteers. The purpose of the study is to demonstrate the non-inferiority of pharmacokinetics, pharmacodynamics and tolerability parameters after single subcutaneous injection. Each dtug will be administered to each volunteer at a dose of 44 µg as a single subcutaneous injection with an interval of at least 14 days.


Condition Intervention Phase
Healthy
Drug: Interferon beta-1a
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: International Multicenter Randomized Double-blind Crossover Study of Pharmacokinetics, Pharmacodynamics and Tolerability of BCD-033 (CJSC BIOCAD, Russia) and Rebif® (Merck Serono S.p.А., Italy) After Single Subcutaneous Administration to Healthy Volunteers

Resource links provided by NLM:


Further study details as provided by Biocad:

Primary Outcome Measures:
  • area under concentration-time curve (AUC) of interferon (IFN) beta-1a from the moment of drug administration until 48 hours and to infinity(AUC(0-48) and AUC(0-∞) respectively) [ Time Frame: up to 48 h ] [ Designated as safety issue: No ]
    Primary outcome measure for pharmacokinetics analysis

  • Cmax of interferon beta-1a [ Time Frame: up to 48 h ] [ Designated as safety issue: No ]
    Primary outcome measure for pharmacokinetics analysis

  • AUC(0-168) and AUC(0-∞) of neopterin and MxA protein [ Time Frame: up to 168 h ] [ Designated as safety issue: No ]
    Primary outcome measure for pharmacodynamics analysis


Secondary Outcome Measures:
  • Тmax of interferon beta-1a [ Time Frame: up to 48 h ] [ Designated as safety issue: No ]
    Secondary outcome measure for pharmacokinetics analysis

  • Т½ of interferon beta-1a [ Time Frame: up to 48 h ] [ Designated as safety issue: No ]
    Secondary outcome measure for pharmacokinetics analysis

  • Кel of interferon beta-1a [ Time Frame: up to 48 h ] [ Designated as safety issue: No ]
    Secondary outcome measure for pharmacokinetics analysis

  • Cl of interferon beta-1a [ Time Frame: up to 48 h ] [ Designated as safety issue: No ]
    Secondary outcome measure for pharmacokinetics analysis

  • Cmax of neopterin and MxA protein [ Time Frame: up to 168 h ] [ Designated as safety issue: No ]
    Secondary outcome measure for pharmacodynamics analysis

  • Tmax of neopterin and MxA protein [ Time Frame: up to 168 h ] [ Designated as safety issue: No ]
    Secondary outcome measure for pharmacodynamics analysis

  • Adverse event (AE) and serious adverse event (SAE) incidence [ Time Frame: up to Day 43 ] [ Designated as safety issue: Yes ]
    Secondary outcome measure for safety assessment

  • AE of garde 3-4 incidence [ Time Frame: up to Day 43 ] [ Designated as safety issue: Yes ]
    Secondary outcome measure for safety assessment

  • Local reaction incidence [ Time Frame: up to Day 43 ] [ Designated as safety issue: Yes ]
    Secondary outcome measure for tolerability assessment

  • Study withdrawal rate due to AE [ Time Frame: up to Day 43 ] [ Designated as safety issue: Yes ]
    Secondary outcome measure for safety assessment


Enrollment: 32
Study Start Date: February 2013
Study Completion Date: August 2013
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BCD-033 → Rebif
Volunteers in this group initially will receive a single sc injection of the study drug BCD-033 (interferon beta-1a) at a dose of 44 µg (on Day 1) and then, after at least 14 days, a single sc injection of the reference drug Rebif® (interferon beta-1a) at a dose of 44 µg.
Drug: Interferon beta-1a
Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.
Other Names:
  • BCD-033
  • Rebif
Experimental: Rebif → BCD-033
Volunteers in this group initially will receive a single sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg (on Day 1) and then, after at least 14 days, a single sc injection of the study drug BCD-033 (interferon beta-1a) at a dose of 44 µg.
Drug: Interferon beta-1a
Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.
Other Names:
  • BCD-033
  • Rebif

Detailed Description:

Each dtug (BCD-033 and Rebif) will be administered to each volunteer at a dose of 44 µg as a single subcutaneous injection with an interval of at least 14 days.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Written informed consent;
  • Male gender;
  • Age 18 - 45 years inclusive;
  • Body mass index (BMI) (18,5 - 24,99 kg/m2);
  • Healthy condition proven by the volunteer's history, global assessment and laboratory analysis results:
  • Absence in past medical history and at screening of clinically significant dysfunctions of circulatory, respiratory, nervous, hematopoietic, endocrine and digestive systems, liver and kidneys;
  • Haematology and biochemistry tests, urinalysis and thyroid hormone analysis results are within normal limits according to standards of the study site. Screening laboratory analyses should be performed not more than 14 days before volunteer's inclusion in the study;
  • Hemodynamic parameters are within normal limits: systolic blood pressure - from 100 to 139 mmHg, diastolic blood pressure - from 60 to 90 mmHg, heart rate - from 50 to 90 bpm;
  • Absence of history of chronic infection (tuberculosis) and chronic inflammation;
  • Absence of HIV, hepatitis B and C virus, syphilis;
  • Absence of acute infections within 4 weeks before inclusion in the study;
  • Absence of psychiatric disorders and other conditions that can interfere with volunteer's ability to follow the study protocol, including depression;
  • Well-being (in volunteer's opinion) within 30 days before participation in the study;
  • Absence of history of systematic alcohol and drug abuse;
  • Ability of the volunteer, in investigator's opinion, to follow the study protocol procedures and requirements;
  • Willingness of volunteers and their sexual partners of childbearing potential to use reliable contraception methods starting from 2 weeks before inclusion into the study and until 4 weeks after receiving the last dose of the investigational products. This criterion is not applicable to patients who underwent surgical sterilization. Reliable contraceptive measures include one barrier method in combination with one of the following methods: spermicides, intrauterine device or oral contraceptives used by participant's partner;
  • Consent to avoid alcohol intake within 24 hours before and 8 days after each administration of the test or reference drugs;
  • Consent to avoid grapefruit juice (or other products containing grapefruit) intake within 72 hours before and 8 days after each administration of the study or reference drugs.

Exclusion Criteria:

  • Previous use of IFN-β1-containing medications at any time before inclusion;
  • History of serious allergic reactions (anaphylaxis or multiple allergy);
  • Known allergy or intolerance to interferons or any other components of study or reference drugs;
  • Major surgery within 30 days before screening;
  • Impossibility to install venous catheter for blood sampling (e.g. because of skin disorders at the sites of venipuncture);
  • Diseases or other conditions that can interfere with the investigational drugs pharmacokinetics (e.g. chronic liver, kidney, blood, circulatory system, lung or neuroendocrine diseases, including diabetes mellitus and others);
  • History of epileptic seizures;
  • Regular oral or parenteral use of any medications including over-the-counter drugs, vitamins and nutritional additives within less than 2 weeks before inclusion in the study;
  • Intake of medications, including over-the-counter drugs and biologically active additives that can influence hemodynamics, liver function etc. (barbiturates, omeprazole, cimetidine etc.) within less than 30 days before inclusion in the study;
  • Intake of medications that influence immune status (cytokines and their inductors, glucocorticoids etc.) within less than 30 days before participation in the study;
  • Smoking more than 10 cigarettes per day;
  • Subjects who consume more than 10 units of alcohol per week or who have history of alcohol abuse or evidence of drug/chemical abuse (one unit of alcohol equals ½ l [500 ml] of beer, one glass [200 ml] of wine or l shot glass [50 ml] of spirits);
  • Donation of 450 ml and more of blood or plasma within 2 months before inclusion in the study;
  • Participation in other clinical studies within less than 1 month before inclusion in the study or simultaneous participation in another clinical study;
  • Previous participation in this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01766024

Locations
Russian Federation
City Mariin Hospital
St. Petersburg, Russian Federation, 194104
Sponsors and Collaborators
Biocad
Investigators
Principal Investigator: Ivan Sardaryan, PhD City Mariin Hospital
  More Information

Additional Information:
No publications provided

Responsible Party: Biocad
ClinicalTrials.gov Identifier: NCT01766024     History of Changes
Other Study ID Numbers: BCD-033-1
Study First Received: January 10, 2013
Last Updated: January 10, 2014
Health Authority: Russian Federation: Ministry of Health of the Russian Federation

Keywords provided by Biocad:
interferon beta-1a
pharmacokinetics
pharmacodynamics
volunteers

Additional relevant MeSH terms:
Interferon beta 1a
Interferon-beta
Interferons
Adjuvants, Immunologic
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 20, 2014